Evidence map›Paper›PMID 24988410›Full record

ArticlePloS one2014

Is peripheral immunity regulated by blood-brain barrier permeability changes?

Erin Bargerstock, Vikram Puvenna, Philip Iffland, Tatiana Falcone, Mohammad Hossain, Stephen Vetter, Shumei Man, Leah Dickstein, Nicola Marchi, Chaitali Ghosh and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. S100B, Actor and Biomarker of Mild Traumatic Brain Injury.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Cellular and molecular mechanisms of sarcopenia: the S100B perspective.Journal of cachexia, sarcopenia and muscle · 2018
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Erin BargerstockCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Vikram PuvennaCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Biomedical Engineering, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Philip IfflandCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Kent State University, Kent, Ohio, United States of America.
Tatiana FalconeCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Psychiatry, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Mohammad HossainCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Biomedical Engineering, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Stephen VetterCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Shumei ManCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Leah DicksteinCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Nicola MarchiCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Chaitali GhoshCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Biomedical Engineering, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Juliana Carvalho-TavaresCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America.
Damir JanigroCerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Department of Biomedical Engineering, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States of America; Flocel, Inc. Cleveland, Ohio, United States of America.
Cleveland Clinic Lerner College of Medicine · USKent State University · US

Funding

Drug brain biotransformation in human refractory epilepsyR01NS078307 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI GHOSH, CHAITALI, MARCHI, NICOLA · 2012 to 2016
$1.7M
MECHANISMS OF MULTIDRUG RESISTANCER01NS043284 · NINDS · CLEVELAND CLINIC LERNER COL/MED-CWRU · PI JANIGRO, DAMIR · 2002 to 2005
$1.3M
Development of a BBB model to study transendothelial cell migrationR42MH093302 · NIMH · FLOCEL, INC. · PI JANIGRO, DAMIR · 2012 to 2013
$1.0M
Serum markers of football-related brain concussions: a pilot studyR21NS077236 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI JANIGRO, DAMIR · 2011 to 2012
$393k
Development of predictive in vitro model of drug absorption across the human BBBR21HD057256 · NICHD · CLEVELAND CLINIC LERNER COM-CWRU · PI JANIGRO, DAMIR · 2009 to 2010
$391k
Development of a BBB Model to Study Transendothelial Cell MigrationR41MH093302 · NIMH · FLOCEL, INC. · PI JANIGRO, DAMIR · 2010 to 2011
$158k
NICHD NIH HHS R21 HD057256NICHD NIH HHS R21HD057256NIMH NIH HHS R41 MH093302NIMH NIH HHS R41MH093302NIMH NIH HHS R42 MH093302NIMH NIH HHS R42MH093302NINDS NIH HHS R01 NS043284NINDS NIH HHS R01 NS078307NINDS NIH HHS R01NS078307NINDS NIH HHS R01NS43284NINDS NIH HHS R21 NS077236NINDS NIH HHS R21NS077236
6 · The paper itself

Abstract

S100B is a reporter of blood-brain barrier (BBB) integrity which appears in blood when the BBB is breached. Circulating S100B derives from either extracranial sources or release into circulation by normal fluctuations in BBB integrity or pathologic BBB disruption (BBBD). Elevated S100B matches the clinical presence of indices of BBBD (gadolinium enhancement or albumin coefficient). After repeated sub-concussive episodes, serum S100B triggers an antigen-driven production of anti-S100B autoantibodies. We tested the hypothesis that the presence of S100B in extracranial tissue is due to peripheral cellular uptake of serum S100B by antigen presenting cells, which may induce the production of auto antibodies against S100B. To test this hypothesis, we used animal models of seizures, enrolled patients undergoing repeated BBBD, and collected serum samples from epileptic patients. We employed a broad array of techniques, including immunohistochemistry, RNA analysis, tracer injection and serum analysis. mRNA for S100B was segregated to barrier organs (testis, kidney and brain) but S100B protein was detected in immunocompetent cells in spleen, thymus and lymph nodes, in resident immune cells (Langerhans, satellite cells in heart muscle, etc.) and BBB endothelium. Uptake of labeled S100B by rat spleen CD4+ or CD8+ and CD86+ dendritic cells was exacerbated by pilocarpine-induced status epilepticus which is accompanied by BBBD. Clinical seizures were preceded by a surge of serum S100B. In patients undergoing repeated therapeutic BBBD, an autoimmune response against S100B was measured. In addition to its role in the central nervous system and its diagnostic value as a BBBD reporter, S100B may integrate blood-brain barrier disruption to the control of systemic immunity by a mechanism involving the activation of immune cells. We propose a scenario where extravasated S100B may trigger a pathologic autoimmune reaction linking systemic and CNS immune responses.

Indexed as

AutoimmunityCapillary PermeabilityImmunity, CellularAmino Acid SequenceAnimalsBlood-Brain BarrierHumansMaleMolecular Sequence DataRats, Sprague-DawleyRNA, MessengerS100 Calcium Binding Protein beta SubunitSeizuresRNA, MessengerS100 Calcium Binding Protein beta Subunit

Identifiers

PMID24988410
PMCPMC4079719
OpenAlexW2079616411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.